Clascoterone vs RU-58841
FDA Approved vs Limited Research
monitor Researched · 90% Both clascoterone and RU-58841 are androgen receptor antagonists applied topically to block DHT at the follicle. Using both simultaneously provides overlapping rather than complementary mechanisms and could increase the risk of local irritation or, theoretically, additive anti-androgenic effects if absorption occurs. There is no clinical rationale for combining two topical AR antagonists; one or the other is recommended.
Molecular Data
Clascoterone RU-58841
Weight 388.54 Da 369.34 Da
Half-life Short topical (local action; rapidly metabolized to cortexolone) ~1 hour topically (very short systemic half-life)
Type Steroidal androgen receptor inhibitor Non-steroidal anti-androgen
Key Benefits
Clascoterone
01 First-in-class topical androgen receptor inhibitor with FDA approval for acne
02 Blocks androgen action locally at the sebaceous gland and hair follicle without systemic hormonal effects
03 Suitable for both men and women, unlike systemic anti-androgens
04 Rapidly metabolized to inactive cortexolone, limiting systemic exposure
05 No clinically meaningful effects on systemic testosterone, DHT, or gonadotropin levels
06 Addresses the root androgen-driven pathology of both acne and androgenetic alopecia
RU-58841
01 Blocks DHT directly at the androgen receptor in hair follicles without reducing systemic DHT levels
02 Extremely short systemic half-life limits risk of systemic anti-androgenic side effects
03 Different mechanism of action from finasteride/dutasteride, allowing combination therapy
04 Animal studies demonstrated significant hair regrowth in androgen-dependent alopecia models
05 Topical application targets the site of action directly
06 Does not interfere with systemic testosterone or DHT levels
Side Effects
Clascoterone
Application site irritation, redness, or dryness
Pruritus (itching) at the application site
Contact dermatitis in sensitive individuals
RU-58841
Scalp irritation, dryness, or itching at the application site (often related to the vehicle/solvent rather than RU-58841 itself)
Contact dermatitis in sensitive individuals
Scalp flaking or peeling
Contraindications
Known hypersensitivity to clascoterone or any component of the formulation
Women who are pregnant or planning to become pregnant (anti-androgens carry theoretical teratogenic risk)
Women who are breastfeeding (safety not established)
Active skin infections at the intended application site
Women who are pregnant or may become pregnant (anti-androgens can cause feminization of a male fetus)
Women who are breastfeeding
Known hypersensitivity to RU-58841 or related non-steroidal anti-androgens
Active scalp infections, open wounds, or severely compromised skin barrier on the scalp
Individuals taking systemic anti-androgens (risk of additive anti-androgenic effects)
Research Evidence
Clascoterone RU-58841
Status FDA Approved Limited Research
References 4 studies 4 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.